相似文献
1
Understanding Early and Late Endpoints in Registrational Trials of Community-acquired Bacterial Pneumonia.
Clin Infect Dis. 2021 Nov 2;73(9):e2613-e2615. doi: 10.1093/cid/ciaa853.
2
Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health.
Clin Infect Dis. 2012 Oct;55(8):1114-21. doi: 10.1093/cid/cis566. Epub 2012 Jun 28.
3
Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Drugs. 2012 Jul 30;72(11):1473-93. doi: 10.2165/11635660-000000000-00000.
4
Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
Drugs. 2021 Feb;81(2):233-256. doi: 10.1007/s40265-020-01443-4.
5
Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).
J Chemother. 2016 Jun;28(3):180-6. doi: 10.1179/1973947815Y.0000000010.
6
Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment.
Int J Antimicrob Agents. 2021 Feb;57(2):106263. doi: 10.1016/j.ijantimicag.2020.106263. Epub 2020 Dec 14.
7
Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection.
Clin Drug Investig. 2022 Mar;42(3):193-197. doi: 10.1007/s40261-022-01119-9. Epub 2022 Feb 22.
8
Concordance of Early and Late End Points for Community-acquired Bacterial Pneumonia Trials.
Clin Infect Dis. 2021 Nov 2;73(9):e2607-e2612. doi: 10.1093/cid/ciaa860.
9
Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.
Expert Rev Clin Pharmacol. 2015 Jan;8(1):141-53. doi: 10.1586/17512433.2015.986461. Epub 2014 Dec 3.
10
Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections.
J Manag Care Spec Pharm. 2023 Aug;29(8):952-964. doi: 10.18553/jmcp.2023.22454. Epub 2023 Jun 12.
本文引用的文献
1
Concordance of Early and Late End Points for Community-acquired Bacterial Pneumonia Trials.
Clin Infect Dis. 2021 Nov 2;73(9):e2607-e2612. doi: 10.1093/cid/ciaa860.
2
Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice.
Clin Infect Dis. 2019 Aug 1;69(Suppl 1):S33-S39. doi: 10.1093/cid/ciz397.
3
Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance.
Clin Infect Dis. 2017 Jul 1;65(1):141-146. doi: 10.1093/cid/cix246.
4
Early Clinical Response as a Predictor of Late Treatment Success in Patients With Acute Bacterial Skin and Skin Structure Infections: Retrospective Analysis of 2 Randomized Controlled Trials.
Clin Infect Dis. 2017 Jan 15;64(2):214-217. doi: 10.1093/cid/ciw750. Epub 2016 Dec 21.
5
The Early Clinical Response Endpoint: Great Timing by the Food and Drug Administration?
Clin Infect Dis. 2017 Jan 15;64(2):218-220. doi: 10.1093/cid/ciw752. Epub 2016 Dec 21.
6
Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health.
Clin Infect Dis. 2016 Mar 1;62(5):603-7. doi: 10.1093/cid/civ927. Epub 2015 Dec 13.
7
Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance.
Antimicrob Agents Chemother. 2015 Oct;59(10):6170-4. doi: 10.1128/AAC.00471-15. Epub 2015 Jul 27.
8
A collaborative model for endpoint development for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.
Clin Infect Dis. 2012 Oct;55(8):1122-3. doi: 10.1093/cid/cis567. Epub 2012 Jun 28.
9
Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health.
Clin Infect Dis. 2012 Oct;55(8):1114-21. doi: 10.1093/cid/cis566. Epub 2012 Jun 28.
10
Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
Clin Infect Dis. 2008 Apr 15;46(8):1142-51. doi: 10.1086/533441.
Zotero 插件